Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin. This type of research is brilliant. It is only in a mouse model, so we do not yet know if it applies to humans. They looked at tumors that became resistant to BCNU and Temodar and found that the changes that allowed the resistance to these drugs opened the door for different drugs to work.
Doxorubicin has been shown to be effective against brain tumor cells in the test tube but it is hard to get a high level of it in the brain so it is not used much today. 10 years ago there was a paper (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635000/) reporting on using Doxorubicin wafers implanted into rat brain tumor and they did pretty well. It may be time to look at this again especially for recurrent GBMs that became resistant to temodar.
